Patents by Inventor Ho Jong Yoon

Ho Jong Yoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10570311
    Abstract: The present invention relates to a laminate including a coating layer, which includes an Si—O group-containing material and an intermediate interface layer, and to a method for producing the same, and more specifically, to a laminate which includes an intermediate interface layer, which is a mixture of materials constituting a substrate and materials constituting a coating layer, between the substrate and the coating layer, which includes an Si—O group-containing material, and thus can significantly improve bending capabilities, transparency, and adhesion between the substrate and the coating layer, and further enhances scratch resistance, water repellent properties, anti-fouling properties, fingerprint resistance, thermal stability, gloss properties, and surface hardness by a silsesquioxane coating, and a method for producing the laminate.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: February 25, 2020
    Assignee: DONGJIN SEMICHEM CO., LTD.
    Inventors: Young Min Yoon, Ho Jong Kim, Sung Hyun Lee, Sung Gun Shin
  • Patent number: 10494346
    Abstract: The present invention relates to a novel pyrimidine-4-carboxylic acid derivative having an anticancer activity, and the compound thereof is useful as a drug for treating and preventing tumor diseases, wherein the compound is represented by the Formula 1: or a pharmaceutically acceptable salt thereof, wherein: Q is a C6-C15 aryl group; or a C4-C13 heteroaryl group, wherein the heteroaryl contains 1, 2 or 3 heteroatoms substituted with 1-3 heteroatom(s) selected from the group consisting of nitrogen, oxygen or sulfur; R is a halogen; a C1-C10 haloalkyl substituted with 1-13 halogen atom(s); a C1-C10 alkoxy; a 5- or 6-membered heterocycloalkyl or (CH2)r-R1 wherein the heterocycloalkyl contains 1-2 heteroatom(s) selected from the group consisting of nitrogen and oxygen; R1 is a hydrogen; a C1-C10 alkoxy; amino; mono(C1-C10 alkyl)amino; di(C1-C10 alkyl)amino; or —NHC(O)-phenyl; n is 1, 2, 3, 4, 5, or 6; and r is 0, 1, 2, 3, 4, 5, or 6; and m is 0, 1, 2 or 3.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: December 3, 2019
    Assignees: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Tae Bo Sim, Woo Young Hur, Ho Jong Yoon, Chi Man Song, In Jae Shun, Byeong Yun Lim, Han Na Cho, Seung Hye Choi, Gu Kong, Jeong Yeon Lee
  • Patent number: 10442796
    Abstract: The present invention relates to a novel 2,3,5-substituted thiophene compound having inhibitory activity against kinases, an anticancer agent including the compound as an active ingredient, and a method for preparing the compound.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: October 15, 2019
    Assignees: Korea Institute of Science and Technology, Daegu-Gyeongbuk Medical Innovation Foundation
    Inventors: Tae Bo Sim, Woo Young Hur, Chi Man Song, Ho Jong Yoon, Seung Hye Choi, Han Na Cho, Hwan Geun Choi, Nam Doo Kim, Jung Beom Son, Eun Hwa Ko, Hyun Kyoung Kim, Joong Heui Cho, Seock Yong Kang, So Young Kim, Yi Kyung Ko, Seung Yeon Lee, Suk Kyoon Yoon, Jae Hyun Bae
  • Publication number: 20190135765
    Abstract: The present invention relates to a novel pyrimidine-4-carboxylic acid derivative having an anticancer activity, and the compound of the present invention is useful as a drug for treating and preventing tumor diseases.
    Type: Application
    Filed: March 30, 2017
    Publication date: May 9, 2019
    Inventors: Tae Bo SIM, Woo Young HUR, Ho Jong YOON, Chi Man SONG, In Jae SHUN, Byeong Yun LIM, HanNa CHO, Seung Hye CHOI, Gu KONG, Jeong Yeon LEE
  • Publication number: 20190047993
    Abstract: The present invention relates to a novel 2,3,5-substituted thiophene compound having inhibitory activity against kinases, an anticancer agent including the compound as an active ingredient, and a method for preparing the compound.
    Type: Application
    Filed: August 16, 2018
    Publication date: February 14, 2019
    Inventors: Tae Bo Sim, Woo Young Hur, Chi Man Song, Ho Jong Yoon, Seung Hye Choi, Han Na Cho, Hwan Geun Choi, Nam Doo Kim, Jung Beom Son, Eun Hwa Ko, Hyun Kyoung Kim, Joong Heui Cho, Seock Yong Kang, So Young Kim, Yi Kyung Ko, Seung Yeon Lee, Suk Kyoon Yoon, Jae Hyun Bae
  • Patent number: 10155767
    Abstract: The present invention provides a therapeutic agent of acute myeloid leukemia containing a 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1H)-one compound as an active ingredient, which has proliferation inhibitory activity for a human acute myeloid leukemia cell line OCI-AML3 having a NRAS mutant gene while having low inhibitory activity for wild type NRAS and has activity of inhibiting GCK and ACK1 protein kinases at the same time.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: December 18, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo Sim, Han Na Cho, Eun Hye Ju, Woo Young Hur, Ho Jong Yoon, Chi Man Song
  • Patent number: 10130631
    Abstract: The present invention relates to a therapeutic agent for chronic myelogenous leukemia with reduced drug-resistance and side-effects containing a 1,6-disubstituted indole compound.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: November 20, 2018
    Assignee: Korea Institute of Science and Technology
    Inventors: Tae Bo Sim, Ho Jong Yoon, Woo Young Hur, Yun Ju Nam, Hwan Geun Choi
  • Patent number: 10059717
    Abstract: The present invention provides a pharmaceutical composition, as an effective ingredient, a urea compound having a protein kinase inhibitory activity and containing a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one skeleton, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: August 28, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo Sim, Woo Young Hur, Ho Jong Yoon, Chi Man Song, Eun Hye Ju, Han na Cho, Hwan Geun Choi
  • Patent number: 10040803
    Abstract: The present invention relates to a novel 4-((2-acrylamidophenyl)amino)thieno[3,2-d]pyrimidine-7-carboxamide compound, an anticancer agent containing the compound as an active ingredient and an intermediate compound for preparing the compound.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: August 7, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo Sim, Ho Jong Yoon, In Jae Shin, Yun Ju Nam, Hwan Geun Choi
  • Publication number: 20180148459
    Abstract: The present invention relates to a novel 4-((2-acrylamidophenyl)amino)thieno[3,2-d]pyrimidine-7-carboxamide compound, an anticancer agent containing the compound as an active ingredient and an intermediate compound for preparing the compound.
    Type: Application
    Filed: November 24, 2017
    Publication date: May 31, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Ho Jong YOON, In Jae SHIN, Yun Ju NAM, Hwan Geun CHOI
  • Publication number: 20180065970
    Abstract: The present invention provides a pharmaceutical composition, as an effective ingredient, a urea compound having a protein kinase inhibitory activity and containing a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one skeleton, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 10, 2017
    Publication date: March 8, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Woo Young HUR, Ho Jong YOON, Chi Man SONG, Eun Hye JU, Han na CHO, Hwan Geun CHOI
  • Publication number: 20180065969
    Abstract: The present invention provides a therapeutic agent of acute myeloid leukemia containing a 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1H)-one compound as an active ingredient, which has proliferation inhibitory activity for a human acute myeloid leukemia cell line OCI-AML3 having a NRAS mutant gene while having low inhibitory activity for wild type NRAS and has activity of inhibiting GCK and ACK1 protein kinases at the same time.
    Type: Application
    Filed: August 9, 2017
    Publication date: March 8, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Han Na CHO, Eun Hye JU, Woo Young HUR, Ho Jong YOON, Chi Man SONG
  • Publication number: 20180050036
    Abstract: The present invention relates to a therapeutic agent for chronic myelogenous leukemia with reduced drug-resistance and side-effects containing a 1,6-disubstituted indole compound.
    Type: Application
    Filed: August 15, 2017
    Publication date: February 22, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Ho Jong YOON, Woo Young HUR, Yun Ju NAM, Hwan Geun CHOI
  • Patent number: 9586936
    Abstract: A heteroarylamine compound includes protein kinase inhibition activity, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for preventing and treating a disease caused by abnormal cell growth, which contains the compound as an active ingredient.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: March 7, 2017
    Assignee: KOREA INSTITITUE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo Sim, Ho Jong Yoon, Ji Hye Yoon, Woo Young Hur, Eun Joo Roh, Yeon Ui Kwak
  • Publication number: 20160145240
    Abstract: A heteroarylamine compound includes protein kinase inhibition activity, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for preventing and treating a disease caused by abnormal cell growth, which contains the compound as an active ingredient.
    Type: Application
    Filed: November 20, 2015
    Publication date: May 26, 2016
    Inventors: Tae Bo SIM, Ho Jong YOON, Ji Hye YOON, Woo Young HUR, Eun Joo ROH, Yeon Ui KWAK
  • Patent number: 8871950
    Abstract: The present invention relates to a method for preparing (+)-polyoxamic acid and a novel intermediate compound synthesized during preparation thereof. The preparation method according to the present invention allows preparation of (+)-polyoxamic acid with high optical purity in high yield. In particular, the preparation method is useful for mass production because the process is simple.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: October 28, 2014
    Assignee: Korea Institute of Science and Technology (KIST)
    Inventors: Tae Bo Sim, Ho Jong Yoon, Eun Joo Roh
  • Publication number: 20140155635
    Abstract: Disclosed are a novel resorcyclic acid lactone compound with inhibitory activity against protein kinases, a pharmaceutically acceptable salt thereof, a method for the synthesis thereof, and a pharmaceutical composition for the treatment and prevention of various cancer diseases comprising the same as an active ingredient. The novel resorcyclic acid lactone compound is useful as a therapeutic for cancer diseases, especially blood cancer, inter alia, acute myeloid leukemia (AML).
    Type: Application
    Filed: October 29, 2013
    Publication date: June 5, 2014
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Ho Jong Yoon, Ji Nyeo Kim